Gupta, N., Labotka, R., Liu, G., Hui, A., & Venkatakrishnan, K. (2016). Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: Dose selection for a phase 3 maintenance study. Invest New Drugs.

Gupta, Neeraj, Richard Labotka, Guohui Liu, Ai-Min Hui, và Karthik Venkatakrishnan. "Exposure–safety–efficacy Analysis of Single-agent Ixazomib, an Oral Proteasome Inhibitor, in Relapsed/refractory Multiple Myeloma: Dose Selection for a Phase 3 Maintenance Study." Invest New Drugs 2016.

Gupta, Neeraj, et al. "Exposure–safety–efficacy Analysis of Single-agent Ixazomib, an Oral Proteasome Inhibitor, in Relapsed/refractory Multiple Myeloma: Dose Selection for a Phase 3 Maintenance Study." Invest New Drugs 2016.